Sanofi’s eczema drug hits pri­ma­ry end­point in PhI­Ib tri­al, plans un­der­way for PhI­II in 2024

Sanofi’s an­ti-OX40L an­ti­body, am­lite­limab, passed a 390-pa­tient Phase IIb tri­al by hit­ting the pri­ma­ry end­point, with pa­tients see­ing up to a 61.5% im­prove­ment on a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER